Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 11/20 | 0.81 |
| ▸ | PRKACG | P22612 | 11/20 | 0.81 |
| ▸ | PRKACB | P22694 | 11/20 | 0.81 |
| ▸ | PRKCA | P17252 | 5/20 | 0.81 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.81 |
| ▸ | CDK1 | P06493 | 4/20 | 0.81 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.81 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.81 |
| ▸ | CDK4 | P11802 | 3/20 | 0.81 |
| ▸ | CCND1 | P24385 | 3/20 | 0.81 |
| ▸ | PRKCB | P05771 | 3/20 | 0.81 |
| ▸ | PRKCH | P24723 | 3/20 | 0.81 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.81 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.81 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.81 |
| ▸ | PIM1 | P11309 | 2/20 | 0.81 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.81 |
| ▸ | GSK3B | P49841 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9084477 | 0.94 | PRKACA (0.71) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL9087610 | 0.94 | PRKACA (0.69) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL9083061 | 0.93 | PRKACA (0.81) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL9086759 | 0.91 | PRKACA (0.67) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL9087076 | 0.90 | PRKACA (0.82) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| Gf-109203 SCHEMBL29353725 | 0.90 | PRKACA (1.00) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| Gf-109203 SCHEMBL338086 | 0.90 | PRKACA (1.00) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL7822724 | 0.89 | PRKACA (0.81) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL9086535 | 0.89 | PRKACA (0.81) | PRKACAPRKACGPRKACBPRKCACCNB2 | |
| SCHEMBL9087334 | 0.89 | PRKACA (0.81) | PRKACAPRKACGPRKACBPRKCACCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193235-B2 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | UNIVERSITY OF KANSAS (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193235-B2 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | UNIVERSITY OF KANSAS (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2010144780-A1 | COMPOSITIONS AND METHODS FOR ESTABLISHING AND MAINTAINING STEM CELLS IN AN UNDIFFERENTIATED STATE | UNIVERSITY OF KANSAS (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317100-A1 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | UNIVERSITY OF KANSAS | 2010-12-16 | — | — | US | disclosed |
| US-20100317100-A1 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | UNIVERSITY OF KANSAS | 2010-12-16 | — | — | US | disclosed |
| US-5516915-A | Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317100-A1 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state | MCL1, PRKCA, PRKCI | PRKACA 20/4885PRKACG 16/4885PRKACB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.